Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GnuBIO Inc.

www.gnubio.com

Latest From BioRexis Pharmaceutical Corp.

Merck's Head-long Leap into Follow-On Biologics

Merck outlined ambitious and capital-intensive plans for a biosimilars business at its annual investor day in early December. The company aims to leverage its 2006 acquisition of GlycoFi to launch six or more follow-on biologics between 2012 and 2017. The news shifts the Big Pharma in an entirely new direction, one that pharmaceutical companies--with the exception of Novartis AG's Sandoz division--have largely stayed away from.
BioPharmaceutical Business Strategies

Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Pharma companies are bullish about biologics, seeing them as at least a partial solution for the pipeline troubles and reimbursement challenges bedeviling the industry. The major question is how best to bring these new biologics capabilities in-house--either piecemeal through a series of smaller acquisitions and licensing deals or in one fell swoop through the acquisition of a player with soup-to-nuts capabilities. Both strategies require delicate post-merger management skills, but many feel acquiring an end-to-end player is a faster, less risky solution to filling the biologics gap. But because few end-to-end biologics players are left for acquisition, in the future it seems likely that Big Pharma will be forced to make a serial acquisition strategy work.
BioPharmaceutical Strategy

Start-Up Previews (6/04)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Filling in the Gaps in AAA Repair, features CardioMEMS Inc., EVA Corp. and Medical Metrx Solutions Inc.. Plus these Start-Ups across Health Care: BioRexis Pharmaceutical Corp., Calypso Medical Technologies Inc., Chaperone Technologies Inc., QRxPharma Pty. Ltd. and Sequential Inc.

BioRexis Pharmaceutical Corp.

BioRexis Pharmaceutical hopes to solve the problems with protein drugs by exploiting a previously overlooked human protein as a novel protein fusion scaffold. If the company's technology works, BioRexis could build a diverse product pipeline fast, with much lower manufacturing costs and without any outside IP encumbrance.
BioPharmaceutical
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • GnuBIO Inc.
  • Senior Management
  • John Boyce, Pres. & CEO
    Susie T Harborth, CFO
    Sepehr Kiani, PhD, EVP, Prod. Dev.
  • Contact Info
  • GnuBIO Inc.
    Phone: (617) 446-6744
    1 Kendall Square Bldg.
    Ste. 1400
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register